Return to homepagePandemic Pact

Moderna

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: CEPI-1786

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $50,000,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    99

  • Lead Research Institution

    Moderna

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI has committed up to US$50 million for preclinical testing and Phase 1 clinical trials. CEPI will support simultaneous manufacturing of doses to enable large-scale Phase 2/3 trials to begin immediately if Phase 1 data supports progression. This candidate uses the same fast, flexible, scalable mRNA technology validated during COVID-19 and builds upon Moderna’s existing R&D on related Ebola viruses. The collaboration leverages CEPI's existing strategic partnership with Moderna.